TFF Pharmaceuticals Inc. (TFFP) Tops Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
TFF Pharmaceuticals Reports Second Quarter 2020 Financial and Business Results
August 13, 2020 4:00 PM EDTEnters into worldwide license agreement with UNION Therapeutics for its Thin Film Freezing technology in combination with niclosamide
Closes on $25.9 million private financing to further advance its technology platform for inhalable drug products, vaccines, biologics and botanicals
Completes Phase 1 trial dosing for Voriconazole Inhalation Powder and begins Phase 1 trial for Tacrolimus Inhalation Powder
Conference call and live webcast scheduled for Thursday, August 13, 2020 at 4:30pm EDT
AUSTIN, Texas--(BUSINESS WIRE)-- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical... More
